December 2020
From the first page:
EVIDENCE SUMMARY
- There are no specific guidelines for use of messenger RNA (mRNA) vaccines or contraindications to mRNA vaccines.
- No large trials of any mRNA vaccine have been completed yet.1
- The only evidence on safety of mRNA vaccines comes from small phase I and phase II trials of SARS-CoV-2 vaccines, with
follow-up typically less than two months.- Systemic adverse events such as fatigue, muscle aches, headache, and chills are common.
- Severe systemic adverse events were reported by 5 to 10 percent of trial subjects.2
- Localized adverse events such as pain at the injection side are common.
- Both systemic and local adverse events usually are resolved within one or two days.
- The rate and severity of adverse events appears to be higher for the second dose of vaccine than for the first.
- Higher vaccine doses appear to increase the rate and severity of adverse events.
- Larger trials of SARS-CoV-2 vaccines are in progress, with results expected in mid-2021.1
- There is not sufficient evidence to support any conclusions on the comparative safety of different mRNA vaccines.
- Direct evidence on the comparative safety of mRNA vaccines and other vaccines is lacking.
1. In other words, the January/February 2021 mass rollouts ARE the larger trials. These vaccines were still experimental when they were offered to the public. As such, they cannot legally be mandated by anyone. No one can legally force you to take them. Forcing or coercing anyone into participating in a medical experiment is considered a crime against humanity with a potential punishment of death.
2. This is a very high percentage for severe adverse events.
Source:
- December 2020. Nikhil K. Mull, Matthew D. Mitchell, and Patrick J. Brennan. “Adverse Effects of Messenger RNA Vaccines.” Penn Medicine Center for Evidence-based Practice, University of Pennsylvania.
http://www.uphs.upenn.edu/cep/COVID/mRNA%20vaccine%20review%20final.pdf,
Local copy.
University, PDF.